-
1
-
-
84903904015
-
Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
-
Dimopoulos MA, Delimpasi S, Katodritou E, Vassou A, Kyrtsonis MC, Repousis P et al. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. Ann Oncol 2014; 25: 195–200.
-
(2014)
Ann Oncol
, vol.25
, pp. 195-200
-
-
Dimopoulos, M.A.1
Delimpasi, S.2
Katodritou, E.3
Vassou, A.4
Kyrtsonis, M.C.5
Repousis, P.6
-
2
-
-
84965050407
-
International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
-
Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol 2016; 34: 1544–1557.
-
(2016)
J Clin Oncol
, vol.34
, pp. 1544-1557
-
-
Dimopoulos, M.A.1
Sonneveld, P.2
Leung, N.3
Merlini, G.4
Ludwig, H.5
Kastritis, E.6
-
4
-
-
0028824562
-
Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases
-
Torra R, Blade J, Cases A, Lopez-Pedret J, Montserrat E, Rozman C et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.
-
(1995)
Br J Haematol
, vol.91
, pp. 854-859
-
-
Torra, R.1
Blade, J.2
Cases, A.3
Lopez-Pedret, J.4
Montserrat, E.5
Rozman, C.6
-
5
-
-
0033851432
-
Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Nordic Myeloma Study Group
-
Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.
-
(2000)
Eur J Haematol
, vol.65
, pp. 175-181
-
-
Knudsen, L.M.1
Hjorth, M.2
Hippe, E.3
-
6
-
-
0025294041
-
Renal failure in multiple myeloma. Pathogenesis and prognostic implications
-
Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695.
-
(1990)
Arch Intern Med
, vol.150
, pp. 1693-1695
-
-
Alexanian, R.1
Barlogie, B.2
Dixon, D.3
-
7
-
-
0032575885
-
Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution
-
Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.
-
(1998)
Arch Intern Med
, vol.158
, pp. 1889-1893
-
-
Blade, J.1
Fernandez-Llama, P.2
Bosch, F.3
Montoliu, J.4
Lens, X.M.5
Montoto, S.6
-
8
-
-
85014602497
-
Evolution in the treatment of multiple myeloma and impact on dialysis inde-pendence: Data from a French cohort from 1999 to 2014
-
Laforet M, Jourde-Chiche N, Haddad F, Sallee M, Stoppa AM, Brunet P et al. Evolution in the treatment of multiple myeloma and impact on dialysis inde-pendence: data from a French cohort from 1999 to 2014. Blood Cancer J 2016; 6: e409.
-
(2016)
Blood Cancer J
, vol.6
, pp. e409
-
-
Laforet, M.1
Jourde-Chiche, N.2
Haddad, F.3
Sallee, M.4
Stoppa, A.M.5
Brunet, P.6
-
9
-
-
85020620007
-
High cut-off haemodialysis(HCO-HD) does not improve outcomes in myeloma cast nephro-pathy: Results of European trial of Free Light Chain removal extended haemo-dialysis in cast nephropathy (EULITE)
-
Abstract P270
-
Cook M, Hutchison C, Fifer L, Gillmore J, Heyne N, Weisel K et al. High cut-off haemodialysis(HCO-HD) does not improve outcomes in myeloma cast nephro-pathy: results of European trial of Free Light Chain removal extended haemo-dialysis in cast nephropathy (EULITE). EHA 2016; Abstract P270.
-
(2016)
EHA
-
-
Cook, M.1
Hutchison, C.2
Fifer, L.3
Gillmore, J.4
Heyne, N.5
Weisel, K.6
-
10
-
-
85020601456
-
Treatment of myeloma cast nephropathy (MCN): A randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Inter-groupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))
-
Bridoux F, Pegourie B, Augeul-Meunier K, Royer B, Joly B, Lamy T et al. Treatment of myeloma cast nephropathy (MCN): a randomized trial comparing intensive haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a bortezomib-based regimen (the MYRE Study, by the Inter-groupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)). Blood 2016; 128: 978–978.
-
(2016)
Blood
, vol.128
, pp. 978
-
-
Bridoux, F.1
Pegourie, B.2
Augeul-Meunier, K.3
Royer, B.4
Joly, B.5
Lamy, T.6
-
11
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
-
(2006)
Leukemia
, vol.20
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
Blade, J.4
Barlogie, B.5
Anderson, K.6
-
12
-
-
34547706021
-
Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents
-
Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546–549.
-
(2007)
Haematologica
, vol.92
, pp. 546-549
-
-
Kastritis, E.1
Anagnostopoulos, A.2
Roussou, M.3
Gika, D.4
Matsouka, C.5
Barmparousi, D.6
-
13
-
-
57349152434
-
Bortezomib-induced survival signals and genes in human proximal tubular cells
-
Sarkozi R, Perco P, Hochegger K, Enrich J, Wiesinger M, Pirklbauer M et al. Bortezomib-induced survival signals and genes in human proximal tubular cells. J Pharmacol Exp Ther 2008; 327: 645–656.
-
(2008)
J Pharmacol Exp Ther
, vol.327
, pp. 645-656
-
-
Sarkozi, R.1
Perco, P.2
Hochegger, K.3
Enrich, J.4
Wiesinger, M.5
Pirklbauer, M.6
-
14
-
-
84951020021
-
Revised international staging system for multiple myeloma: A report from international myeloma working group
-
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015; 33: 2863–2869.
-
(2015)
J Clin Oncol
, vol.33
, pp. 2863-2869
-
-
Palumbo, A.1
Avet-Loiseau, H.2
Oliva, S.3
Lokhorst, H.M.4
Goldschmidt, H.5
Rosinol, L.6
-
15
-
-
85014448913
-
Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma
-
Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E et al. Evaluation of the revised international staging system (R-ISS) in an independent cohort of unselected patients with multiple myeloma. Hae-matologica 2016; 102: 593–599.
-
(2016)
Hae-Matologica
, vol.102
, pp. 593-599
-
-
Kastritis, E.1
Terpos, E.2
Roussou, M.3
Gavriatopoulou, M.4
Migkou, M.5
Eleutherakis-Papaiakovou, E.6
|